Kornimate/medical-research-clean huggingface dataset:
moxifloxacin versus ceftriaxone in the treatment of primary pyogenic liver abscess

Conditions: Liver Abscess

Summary: this clinical trial compares the use of moxifloxacin versus ceftriaxone in the treatment of primary pyogenic liver abscess. the trial will include nonpregnant adults presenting with primary liver abscess based on clinical diagnosis and computed tomography. the trial aims to determine whether the use of moxifloxacin can effectively treat primary pyogenic liver abscess and shorten hospitalization. this regimen has the additional benefit of avoiding nephrotoxic agents, such as aminoglycosides, used frequently in treatment of pyogenic liver abscess. development of antibiotic resistance to colonized bacteria in the gastrointestinal tract will also be evaluated using stool cultures.


Eligibility criteria:
inclusion criteria: * age greater or equal to 20 years. * clinical diagnosis of liver abscess, supported by an abdominal ct scan, documenting the presence of liver abscess, in the absence of biliary tract stones (except for gallstones without biliary tract dilatation), biliary tract dilatation and biliary tract tumors. clinical diagnosis of liver abscess includes symptoms of fever, chills, right upper quadrant abdominal pain or knocking tenderness. * read, understood and signed informed consent form. exclusion criteria: * presence of septic metastatic infections to the cns or eye at presentation. * cultures positive for an organism resistant to study drugs. * apache ii score greater or equal to 20. * co-existent disease considered likely to affect the outcome of the study (e.g., biliary tract stones and malignancy). * patients with ruptured liver abscess * severe hepatic insufficiency (child-pugh c) or elevated serum transaminases (gpt) to greater than 5 times the upper limit of normal. * patients who are pregnant or lactating. * known hypersensitivity to b-lactams or fluoroquinolones. * known prolongation of the qt interval. * patients with uncorrected hypokalemia. * patients receiving class ia (e.g., quinidine, procainamide) or class iii (e.g., amiodarone, sotalol) antiarrhythmic agents * severe, life-threatening disease with a life expectancy of less than 2 months. * pre-treatment with a systemic antibacterial agent for \> 24 hours prior to enrollment within 5 days prior to enrollment. * participated in any clinical investigational drug study within 4 weeks of screening. * previously entered in this study.

Keywords: liver abscess moxifloxacin ceftriaxone treatment
prognostic impact of anatomical resection vs. non-anatomical resection for hcc

Conditions: Patients Affected by Hepatocellular Carcinoma; Disease-Free Survival; Overall Survival

Summary: prognostic impact of ar vs nar

whether anatomical is better than non anatomical resection for hcc is still debated. this prospective randomized study aimed to address which approach is better in terms of patients prognosis.

Eligibility criteria:
inclusion criteria: * patient affected by single hcc * patients in whom liver resection is indicated * hcc without vascular invasion and/or thrombosis exclusion criteria: * multinodular hcc * metastatic disease * spontaneous tumor rupture

Keywords: anatomical resection non-anatomical resection ious-guided finger compression
fecal calprotectin levels, quality of life, and workability in patients suffering from ulcerative colitis under adalimumab therapy - adaproquo

Conditions: Moderate to Severe Ulcerative Colitis

Summary: the objectives of this study are to explore the fecal calprotectin (fc) levels of uc patients under adalimumab therapy and the correlation with their general wellbeing (quality of life \[qol\]), workability, and disease activity.

this is a non-interventional, observational study in which humira (adalimumab) is prescribed in the usual manner in accordance with the terms of the local marketing authorization with regards to dose, population and indication. the assignment of the patient to a adalimumab containing regimen has to be decided in advance and has to be current practice. the prescription of adalimumab is clearly separated from the decision to include the participant in this study.

Eligibility criteria:
inclusion criteria: * patients with moderate to severe ulcerative colitis (uc) who have not responded despite a full and adequate course of therapy with a corticosteroid and an immunosuppressant (aza/6-mp); or who are intolerant to or have medical contraindications for such therapies and are hence prescribed adalimumab for the treatment of moderate to severely active uc * patients who are able to complete patients questionnaires (e.g., wpai:uc and sibdq questionnaire) * patients must fulfill national and international guidelines for the use of biologic therapies in uc (chest x-ray and interferon-gamma-release assay (igra) or tuberculin purified protein derivative (ppd)-skin test negative for tuberculosis). * patients who have been prescribed adalimumab in line with the european smpc (summary of product characteristics) exclusion criteria: * previous therapy with tnf-alpha (tumor necrosis factor alpha) blocker * no signed written authorization to use data * contraindication to adalimumab therapy according to the smpc * patients with a history of subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, koch pouch, or ileostomy for uc or planned bowel surgery. * patients received intravenous (iv) corticosteroids within 14 days of screening or during the screening period. * pregnant patients

Keywords: ulcerative colitis inflammatory bowel syndrome adalimumab tumor necrosis factor (tnf) alpha antibody calprotectin
efficacy of two protocols for applying fluorine varnish to deciduous teeth

Conditions: Dental Caries

Summary: evidence that the data flow analysis tests, there are still no studies that show the clarity of the protocols of its application, including the interval and execution factors of applications, concentration of fluoridation and previous prophylaxis. that is, there are still large gaps regarding fluoride varnish applications. thus, the objective of the present project is the selection of two protocols for application of fluid applications in active drugs in primary tooth enamel. the longitudinal follow-up will be performed in a period of 3, 6, 12, 18 and 24 months after the procedure. the progression of a subject will be evaluated clinically through the transition of icdas scores and assessment of the lesions (sound examination with superficial measurements) by visual examination, and the physician evaluates the efficacy and the ability to evaluate the therapeutic techniques and evaluation. treatment, cost and quality of life of participants


Eligibility criteria:
inclusion criteria: * children with active carious lesions scores 1, 2 or 3 of the icdas in deciduous teeth exclusion criteria: * patients with special needs; * patients using orthodontic appliances; * systemic diseases; * teeth that present restorations, sealants, formation defects, deep caries lesions that may lead to pulp involvement, fistulae and / or abscesses; * teeth with spontaneous painful symptomatology.

Keywords: dental caries tooth, deciduous fluorides, topical
probiotics: clinical intervention trial in patients with fibromyalgia

Conditions: Fibromyalgia

Summary: this study evaluates the benefits of probiotics in patients with fibromyalgia syndrome.

probiotics has demonstrated to be effective in the management of anxiety and depression. although these results are promising, more research is needed to explore the role of probiotics to improve physical, emotional and cognitive processes in different clinical populations that are associated with altered microbiome. thus, the main aim of the present project is to explore whether the oral intake of probiotics might provide benefits to a group of patients with fibromyalgia. the investigators expect to found significant differences between some physical, emotional and cognitive measures assessed pre- and post-treatment demonstrating the effects of microbiota on the central nervous system as well as its potential as a therapeutic tool for the treatment of fibromyalgia.

Eligibility criteria:
inclusion criteria: * fibromyalgia syndrome diagnosis. * no treatment with antibiotic. * more than a year of diagnosis * agreement to participate in the study. exclusion criteria: * severe physical disability. * malignancy. * pregnancy * psychiatric illnesses (eg, schizophrenia or substance abuse). * medication usage other than as-needed analgesics (excluding long-term narcotics).

Keywords: probiotics
impact of vitamin a supplementation on immune system in multiple sclerosis patients

Conditions: Relapsing Remitting Multiple Sclerosis

Summary: the aim of this study is to study the comparison between the effects of supplementation with 25000 iu preformed vitamin a (retinyl palmitate) or placebo for 6 months on immune system and th1/th2 balance in patients with multiple sclerosis.

multiple sclerosis (ms) is a chronic inflammatory disease where th1 like responses from myelin-specific cd4+ t cells, as secretion of pro-inflammatory ifn-g, are believed to play a major role in the pathogenesis. the myelin-specific t cells that mediate tissue destruction in ms are believed to become activated outside the central nervous system (cns) in lymphoid tissue and when they cross the blood brain barrier they will re-encounter their antigen. immune deviation is the redirection of the immune response from most often th1 like responses to th2 like responses, even though the opposite can also occur. vitamin a (va) or va-like analogs known as retinoids, are potent hormonal modifiers of type 1 or type 2 responses but a definitive description of their mechanism(s) of action is lacking. high level dietary vitamin a enhances th2 cytokine production and iga responses, and is likely to decrease th1 cytokine production. retinoic acid inhibits il 12 production in activated macrophages, and ra pretreatment of macrophages reduces ifnγ production and increases il4 production in antigen primed cd4 t cells. supplemental treatment with vitamin a or retinoic acid (ra) decreases ifnγ and increases il5, il10, and il4 production. thus, vitamin a deficiency biases the immune response in a th1 direction, whereas high level dietary vitamin a may bias the response in a th2 direction.

Eligibility criteria:
inclusion criteria: patients who have used interferon beta in last 3 months. patients with 1-5 edss exclusion criteria: * patients who have diseases which affect on th1/th2 balance such as asthma, active viral infections, and autoimmune diseases, or * patients who have allergy to vitamin a compounds, or * patients who have used vitamin supplements in last 3 months.

Keywords: multiple sclerosis vitamin a cd4-positive t-lymphocytes th1 cells th2 cells
levels of matrix metalloproteinase-8 after intrapocket treatment in moderate periodontitis patients.

Conditions: Periodontitis

Summary: using local delivery drugs as adjunctive to scaling and root planing and evaluating gingival crevicular fluid (gcf) biological molecular markers (mmp-8).

study sample and setting a sample size of twenty patients per group (number of groups = 2) (total sample size = 40 patients) is the sufficient required sample as statistically significant with 80% power. the sample size was calculated using g power version 3.1.9.2. patients will be recruited from the outpatient clinic of the department of oral medicine, periodontology, diagnosis and oral radiology. faculty of dentistry, alexandria university. treatment will be in accordance with the principles of the modified helsinki code for human clinical studies (2013). the clinical study will be conducted following the ethical guidelines for conduct of research on human subjects, by the faculty of dentistry, alexandria university (irb no:00010556 - iorg 0008839). data management and statistical analysis the data will be processed and analysed using statistical package for social sciences program spss (20.0) software\*. the study will include descriptive and analytical data. a p-value of less than 0.05 will be considered statistically significant.

Eligibility criteria:
inclusion criteria: 1. patients of both sexes having moderate periodontitis (stage ii), cal 3-4mm. 2. patients' age between 25 and 45 years old. 3. systemically healthy patients. 4. no history of periodontal therapy (surgical and non-surgical) or taken any antibiotic therapy for the past six months. exclusion criteria: 1. history of smoking. 2. patients having previous adverse reaction to the products (or similar products) used in this study. 3. grade c category that has rapid rate of progression. 4. pregnant and lactating women.
ai-guided prognostication and cranial radiotherapy optimization in egfr-tki-treated non-small cell lung cancer patients with baseline brain metastases

Conditions: NSCLC (Advanced Non-small Cell Lung Cancer); Brain Metastasases

Summary: the goal of this observational study is to extract the imaging features of brain lesions and primary lung lesions in nsclc patients with brain metastases by deep learning, as well as common clinicopathological parameters, which are used to construct a multimode model that can accurately predict the treatment efficacy and survival of the third-generation egfr-tki treatment, and to use the model to assist in screening high-risk populations suitable for upfront cranial radiotherapy. participants receiving third-generation egfr-tki treatment will be enrolled in our study and we will collect their regular contrast-enhanced chest ct and contrast-enhanced brain mri for model construction.


Eligibility criteria:
inclusion criteria: * pathologically confirmed non-small cell lung cancer; * clinical stage iv (ajcc, 8th edition, 2017); * egfr sensitive mutations: egfr l858r, egfr exon 19 deletion; * age≥18 years old; * kps score≥70; * brain metastases at diagnosis; * complete systemic imaging (including brain mri) before third-generation egfr-tki treatment; * received standard third-generation egfr-tki therapy (monotherapy or combined with brain radiotherapy); * willing to cooperate with the follow-up after third-generation egfr-tki treatment; * informed consent of the patient. exclusion criteria: * multiple primary or metastatic tumors (except early skin cancer, cervical carcinoma in situ that has been treated radically, with no recurrence or progression for more than 5 years); * pregnant or lactating women who, as judged by the investigator, were not candidates for brain mri; * egfr sensitive mutations were negative or egfr mutation status was not detected. * uncontrolled epilepsy, central nervous system disease, or history of mental disorders, judged by the researcher to potentially interfere with the signing of the informed consent form or affect patient compliance.
safety and pharmacokinetics of recombinant factor xiii in healthy volunteers

Conditions: Congenital Bleeding Disorder; Congenital FXIII Deficiency; Healthy

Summary: this trial was conducted in europe. the aim of this trial was to investigate safety and pharmacokinetics of escalating single doses of catridecacog (recombinant factor xiii, rfxiii) in healthy volunteers.


Eligibility criteria:
inclusion criteria: * normal platelet count and clotting parameters * adequate renal and hepatic function * if female and of child-bearing potential, negative serum pregnancy test within 21 days of enrollment and a negative urine pregnancy test on admission to the clinical research unit * if a sexually active male or a sexually active female of child-bearing potential,agreement to use a medically accepted form of contraception from the time of enrollment to completion of all follow-up study visits * negative drug and alcohol screens exclusion criteria: * known antibodies or hypersensitivity to fxiii * known bleeding or hematologic disorder * known allergy to yeast * receipt of blood products within 30 days of screening * donation of blood within 30 days prior to enrollment * any surgical procedure in the 30 days prior to enrollment * previous history of autoimmune disorders involving autoantibodies, e.g., systemic lupus erythematosus * receipt of treatment with any experimental agent within 30 days of study enrollment
follow-up of early breast cancer (bc) patients by telephone or mobile software

Conditions: Breast Cancer, Early-Onset

Summary: patients with early breast cancer were randomized at the final visit of adjuvant radiotherapy to surveillance by phone calls or by mobile noona software. after six months the groups were crossed over to the other arm. at 12 months the patients were asked their preference which was the primary end-point. at baseline, 6 months and 12 months the patients answered the other questionnaires.

patients with early breast cancer were randomized at the final visit of adjuvant radiotherapy to surveillance by phone calls or by mobile noona software. after six months the groups were crossed over to the other arm. the primary end point was to find out patient preference for the modality of surveillance. secondary endpoints were patient satisfaction, symptoms, quality of life and cost of follow-up during surveillance modalities. at 12 months the patients were asked their preference for the follow-up modality of early breast cancer. at baseline, 6 months and 12 months the patients answered the other questionnaires on quality of life, symptoms, patient satisfaction and use of other health-care services. information on the cost of follow-up was gathered from the hospital and other registries.

Eligibility criteria:
inclusion criteria: * adult patients with early breast cancer after primary treatment including also radiotherapy (the patients were randomized at the final visit of radiotherapy) exclusion criteria: * not able to use a computer * another malignancy

Keywords: follow-up, mobile software, early breast cancer
adherence to fluid intake recommendations in kidney stone patients

Conditions: Urolithiasis

Summary: the cumulative risk of stone recurrence rate is up to 14% at 1 year, 35% at 5 years, and 52% at 10 years. low urine volume caused by insufficient fluid consumption is one of the most crucial risk factors for kidney stone formation. according to the guidelines, a copious fluid intake to maintain a urine volume of at least 2.0 to 2.5 l/24 h is recommended for most kidney stone formers. patients often find it difficult to follow the recommendations in fluid intake, which leads to stone recurrence. therefore, there is a need to improve patient compliance and adherence to following the instructions on keeping water balance. for this purpose we developed a mixed educational program including two parts. the first is the mobile application called "stonemd: kidney stones". the second is the "school for patients" with kidney stones, which is responsible for the stone clinic effect.

the aim of the study is to test the hypothesis that using mixed educational program additionally to standard recommendations in patients after the first stone surgery episode helps to achieve better adherence to daily fluid intake recommendations than the using standard recommendations alone given at the day of discharge.

Eligibility criteria:
inclusion criteria: * low risk recurrence group patients; * patients after the first stone surgery; exclusion criteria: * recurrent cases of stone formation; * patients, who do not have smartphones; * patients, who can't visit "schools for patients" with kidney stone disease;

Keywords: application stonemd schools of patients
polyp histology prediction by artificial intelligence

Conditions: Colorectal Polyp

Summary: we have been developing artificial intelligence based polyp histology prediction (aiphp) method to classify narrow band imaging(nbi) colonoscopy images to predict the hyperplastic or neoplastic histology of polyps. we plan to study colonoscopy polyp samples taken by polypectomy from 1200 patients.the documented nbi still images will be analyzed by the aiphp method and by the nice classification parallel.our aim is to analyze the accuracy of aiphp and nbi classification based histology predictions and also compare the results of the two methods.

background: colonoscopy with polypectomy or early colorectal neoplastic lesions (polyp) is a proven and widely accepted method of reducing colorectal cancer mortality rates. predicting histology prior to endoscopic colorectal polyp removal is useful especially for diminutive (1-5mm) and small (6-10mm ) polyps. evaluation of colorectal polyps using the narrow-band imaging (nbi) technique and the nbi international colorectal endoscopic (nice) classification are useful to predict the histology during endoscopy.however, nbi and magnification based polyp histology prediction needs training and endoscopic experience. morever , the final and objective diagnosis still requires histology. therefore,we have been developing arteficial intelligence-based polyp histology prediction (aiphp) software to automatically evaluate the magnified nbi colonoscopy images aiming the histology prediction of polyps. materials and methods: we plan to examine 1200 colorectal polyps obtained from patients. polyps will be removed by traditional polypectomy or with mucosectomy.endoscopic procedures and histological examinations performed at the participation hospitals. colonoscopy will be performed with olympus exera iii cfhq190i (olympus ,tokyo,japan) high reolution nbi colonoscopes providing 65x optical magnification. colorectal polyps will be detected first by high definition colonoscopy then by nbi at the optical maximum magnification (65x). all studied polyps will be photo-documented. the stored nbi photos were anelyzed by the nice classification and aiphp parallel system. histological examination methods: we use who classification of colorectal polyps. the two -class classification will considere hyperplastic or neoplastic ((ssls,tubular or villous adenomas, and invasive adenocarcinomas). aiphp software systtem: the aiphp software is based on the categorization of the vascular pattern and color of the polyps.the main steps of aiphp software development will be the following: 1) feature vector calculation 2) training of classifier module, and 3) aiphp classifier testing. five features will be used by our aiphp software.

Eligibility criteria:
inclusion criteria: * colorectal polyps removed by polypectomy exclusion criteria: * colorectal polyps with ibd

Keywords: colorectal polyp,histology,artificial intelligence
a 12-month study to evaluate the efficacy and safety of once-daily instillation of combination glaucoma therapy in patients with open-angle glaucoma or ocular hypertension

Conditions: Glaucoma, Open-angle; Ocular Hypertension

Summary: the purpose of this study is to evaluate the intraocular pressure(iop)-lowering efficacy of a combination iop-lowering therapy in patients with open-angle glaucoma or ocular hypertension.


Eligibility criteria:
inclusion criteria: - as specified in protocol exclusion criteria: - as specified in protocol

Keywords: glaucoma poag oag oht